UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported)June 5, 2009
------------------
Anika Therapeutics, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Massachusetts
--------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-21326 04-3145961
--------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
32 Wiggins Avenue, Bedford, Massachusetts 01730
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(781) 457-9000
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(e) Amendment and Restatement of Stock Option Plan.
As previously disclosed, on May 29, 2009, the Board of Directors of
Anika Therapeutics, Inc. (the "Company"), approved an amendment to the Company's
Amended and Restated 2003 Stock Option and Incentive Plan (the "2003 Plan") to
reduce the proposed increase in the number of shares subject to the 2003 Plan
from 1,000,000 to 850,000, which would result in a total of 2,350,000 shares of
common stock being reserved for issuance under the 2003 Plan.
On June 5, 2009, the Company held its annual meeting of stockholders
and based on the certified results, the Company's stockholders approved the 2003
Plan.
A copy of the 2003 Plan, reflecting the 2,350,000 shares of common
stock reserved for issuance, is attached hereto as Exhibit 10.1 and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
10.1 Anika Therapeutics, Inc. Amended and Restated 2003 Stock Option and
Incentive Plan
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANIKA THERAPEUTICS, INC.
Date: June 11, 2009 By: /s/ Kevin W. Quinlan
----------------------------------------
Kevin W. Quinlan
Chief Financial Officer
EXHIBIT INDEX
Exhibit Number Description
10.1 Anika Therapeutics, Inc. Amended and Restated 2003 Stock
Option and Incentive Plan